Medical News

RSS

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Ventas reports substantial growth in third quarter 2009

Ventas, Inc. (“Ventas” or the “Company”) said today that third quarter 2009 normalized Funds From Operations (“FFO”) increased 7.4 percent to $103.4 million, from $96.2 million for the comparable 2008 period. Normalized FFO per diluted common share was $0.66 in the third quarter of 2009, compared to $0.68 in the comparable 2008 period. Weighted average diluted shares outstanding in the third quarter of 2009 were 156.5 million, compared to 141.1 million in the comparable 2008 period.

29 Oct 2009

Prosurgics sells FreeHand laparoscopic camera controller to St. James Hospital in Chicago Heights

St. James Hospital in Chicago Heights, Illinois and surgical robotics company Prosurgics announce today the first U.S. sale of a FreeHand® laparoscopic camera controller for gynecologic surgery.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Reliv International net income down in 2009 third quarter

Reliv International, Inc., a nutrition and direct selling company, today reported third-quarter net sales of $20.9 million vs. $23.9 million in the same quarter of 2008.

29 Oct 2009

Interleukin Genetics and Amway Global sign partnership agreement

Interleukin Genetics, Inc. announced today it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM) brand of genetic tests, including the new Weight Management Genetic Test.

29 Oct 2009

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.

29 Oct 2009

GeneGo to launch new web site with high quality pathway content

GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Gentiva Health Services reports decreased net revenues for 2009 third quarter

Gentiva Health Services, Inc. (Nasdaq: GTIV), a leading provider of comprehensive home health services, today reported the following 2009 third quarter results.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Medifast

Medifast, Inc., a provider of leading clinically proven portion-controlled weight-loss programs, announced today third quarter financial results for the period ended September 30, 2009.

29 Oct 2009

Neogenomics declares third quarter 2009 financial results; significantly improved liquidity position

NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2009.

29 Oct 2009

Encision announces financial results for its second quarter of fiscal year 2010

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its second quarter of fiscal year 2010.

29 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

EB Sport announces the availability two branded fitness kits for men and women

EB Sport Group, a market leader in the creation of personal exercise and fitness products, has announced the availability of the Men’s Health “Ultimate Total-Body Workout” and Women’s Health “Lean Body Workout” – two branded fitness kits designed to get people back in shape quickly.

29 Oct 2009

Third quarter 2009 financial results announced by United Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009.

29 Oct 2009

Bruker Corporation revenue increases by 9.5% in third-quarter 2009

Bruker Corporation today reported financial results for the third quarter ended September 30, 2009.

29 Oct 2009

First Edition: October 29, 2009

Today's headlines are all about the unveiling of the House health bill -- expected later this morning.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Curis

Curis, Inc., a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the third quarter ended September 30, 2009.

29 Oct 2009

Seminar on multiple myeloma

MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces a Friday Satellite Symposium on Multiple Myeloma Preceding the 51st ASH Annual Meeting entitled Unifying Practice Patterns Among Academic and Community Clinicians: Focus on Myeloma.

29 Oct 2009